Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370823 · ClinicalTrials.gov registry record
A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment
A clinical trial, sponsored by Regenexx.
- Terminated
- Registry status
- 20
- Enrollment target
NCT02370823 is a clinical trial that was terminated before completion, run by Regenexx. The registered enrollment target is 20 participants.
The verdict
NCT02370823 was terminated before completion, sponsored by Regenexx.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the levels of proteins and/or cellular components of the synovial fluid that are indicative of microenvironment phenotypes of the osteoarthritic knee compared to unilateral unaffected joints pre-injection to 6 weeks post-Regenexx® SD treatment.
Interventions
- PROCEDURE Regenexx SD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-02 |
| Est. Completion | 2018-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02370823
The ClinicalTrials.gov registry entry for NCT02370823 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regenexx, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Regenexx SD is the first listed.
NCT02370823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02370823 about?
NCT02370823 is a clinical study titled "A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment". The primary objective of this study is to determine the levels of proteins and/or cellular components of the synovial fluid that are indicative of microenvironment phenotypes of the osteoarthritic knee compared to unilateral unaffected joints pre-injection to 6 weeks post-Regenexx® SD treatment.
What is the current status of trial NCT02370823?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2015-02. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02370823?
The interventions under investigation include: Regenexx SD (PROCEDURE).
Who is sponsoring clinical trial NCT02370823?
This trial is sponsored by Regenexx, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.